Novogene Co., Ltd.

Equities

688315

CNE1000052X3

Healthcare Facilities & Services

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
13.24 ^CNY	-0.90%		+3.60%	-43.27%

Apr. 12	Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 27	Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Philrivers announced that it has received $15 million in funding from Insight Venture Management, LLC, Beijing Highthink Pharmaceutical Technology Service Co., Ltd., Novogene Co., Ltd. and other investor

July 06, 2022

Philrivers announced that it has raised $15 million in a round of funding led by investors, Insight Venture Management, LLC and Taiya Capital on July 7, 2022. The transaction also included participation from investors, Beijing Highthink Pharmaceutical Technology Service Co., Ltd., Novogene Co., Ltd. (SHSE:688315).

Latest news about Novogene Co., Ltd.

Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 12	CI
Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Novogene Co., Ltd. announces an Equity Buyback for CNY 160 million worth of its shares.	Feb. 05	CI
Novogene Co., Ltd. authorizes a Buyback Plan.	Feb. 04	CI
Certain A Shares of Novogene Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Novogene Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Novogene Co., Ltd.(XSSC:688315) added to S&P Global BMI Index	23-09-18	CI
Novogene Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-31	CI
Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-12	CI
Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Novogene Announces Deployment of Illumina NovaSeq™ X Plus and PacBio REVIO Sequencing Systems	23-01-05	CI
Novogene Co., Ltd.(SHSE:688315) dropped from Shanghai Stock Exchange Health Care Sector Index	22-12-09	CI
Novogene Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Novogene America Unveils Superpowered Robot Scientist for Autonomously Intelligent NGS Delivery- Falcon II	22-09-07	CI
Novogene Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-10	CI
Philrivers announced that it has received $15 million in funding from Insight Venture Management, LLC, Beijing Highthink Pharmaceutical Technology Service Co., Ltd., Novogene Co., Ltd. and other investor	22-07-06	CI
Novogene Co., Ltd.(SHSE:688315) added to Shanghai Stock Exchange Health Care Sector Index	22-06-13	CI
Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Novogene Co., Ltd.(SHSE:688315) added to Shanghai Stock Exchange A Share Index	22-04-18	CI
Novogene Co., Ltd.(SHSE:688315) added to Shanghai Stock Exchange Composite Index	22-04-13	CI
Certain A Shares of Novogene Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-APR-2022.	22-04-12	CI
Novogene Co., Ltd. announced that it expects to receive CNY 2.27307 billion in funding	22-04-07	CI
Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Novogene Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI
Beijing Novogene Technology Co. Ltd. cancelled the acquisition of 10 Sequel Systems, so-Seq annotation from Pacific Biosciences of California, Inc..	18-01-15	CI

Chart Novogene Co., Ltd.

Duration

Period

More charts

Company Profile

Novogene Co Ltd is a China-based company principally engaged in gene sequencing. The Company mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. Based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The Company's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The Company conducts its businesses in domestic and overseas markets.

Sector

Healthcare Facilities & Services

Calendar

2024-04-23 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Novogene Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.24 CNY

Average target price

21.48 CNY

Spread / Average Target

+62.26%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
NOVOGENE CO., LTD.	-43.27%	762M
SONIC HEALTHCARE LIMITED	-16.65%	8.36B
RADNET, INC.	+40.95%	3.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-32.00%	2.87B
SYNLAB AG	-7.71%	2.47B
DR. LAL PATHLABS LIMITED	-9.65%	2.24B
NEOGENOMICS, INC.	-14.34%	1.81B
FLEURY S.A.	-19.73%	1.56B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.57%	1.23B
METROPOLIS HEALTHCARE LIMITED	+9.70%	1.13B

Medical & Diagnostic Laboratories